A randomized, double-blind, chronic dosing placebo-controlled, parallel group, multicenter, Phase III study to evaluate the efficacy and safety of 2 doses of benralizumab (MEDI-563) in patients with moderate to very severe COPD with a history of COPD

Administered By

Awarded By

Contributors

Start/End

  • August 1, 2016 - January 31, 2019